Citations (58)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Alessandro Rizzo, Raffaella Massafra, Annarita Fanizzi, Lucia Rinaldi, Antonio Cusmai, Agnese Latorre, Gian Maria Zaccaria, Maria Ronchi, Michele Telegrafo, Gennaro Gadaleta-Caldarola, Francesco Giotta, Vito Lorusso & Gennaro Palmiotti. (2022) Adenosine pathway inhibitors: novel investigational agents for the treatment of metastatic breast cancer. Expert Opinion on Investigational Drugs 31:7, pages 707-713.
Read now
Read now
Ivan Shevchenko, Andreas Mathes, Christopher Groth, Svetlana Karakhanova, Verena Müller, Jochen Utikal, Jens Werner, Alexandr V. Bazhin & Viktor Umansky. (2020) Enhanced expression of CD39 and CD73 on T cells in the regulation of anti-tumor immune responses. OncoImmunology 9:1.
Read now
Read now
Theresa L. Whiteside. (2018) FOXP3+ Treg as a therapeutic target for promoting anti-tumor immunity. Expert Opinion on Therapeutic Targets 22:4, pages 353-363.
Read now
Read now
Articles from other publishers (55)
Jason V Evans, Shankar Suman, Mounika Uttam L Goruganthu, Elena E Tchekneva, Shuxiao Guan, Rajeswara Rao Arasada, Anneliese Antonucci, Longzhu Piao, Irina Ilgisonis, Andrey A Bobko, Benoit Driesschaert, Roman V Uzhachenko, Rebecca Hoyd, Alexandre Samouilov, Joseph Amann, Ruohan Wu, Lai Wei, Aaditya Pallerla, Sergey V Ryzhov, Igor Feoktistov, Kyungho P Park, Takefumi Kikuchi, Julio Castro, Alla V Ivanova, Thanigaivelan Kanagasabai, Dwight H Owen, Daniel J Spakowicz, Jay L Zweier, David P Carbone, Sergey V Novitskiy, Valery V Khramtsov, Anil Shanker & Mikhail M Dikov. (2023) Improving combination therapies: targeting A2B-adenosine receptor to modulate metabolic tumor microenvironment and immunosuppression. JNCI: Journal of the National Cancer Institute 115:11, pages 1404-1419.
Crossref
Crossref
Mizuki Izawa, Nobuyuki Tanaka, Tetsushi Murakami, Tadatsugu Anno, Yu Teranishi, Kimiharu Takamatsu, Shuji Mikami, Kazuhiro Kakimi, Takeshi Imamura, Kazuhiro Matsumoto & Mototsugu Oya. (2023) Single-Cell Phenotyping of CD73 Expression Reveals the Diversity of the Tumor Immune Microenvironment and Reflects the Prognosis of Bladder Cancer. Laboratory Investigation 103:4, pages 100040.
Crossref
Crossref
Jasmeet Kaur & Sanchit Dora. (2023) Purinergic signaling: Diverse effects and therapeutic potential in cancer. Frontiers in Oncology 13.
Crossref
Crossref
Xuhui Bao & Liyi Xie. (2022) Targeting purinergic pathway to enhance radiotherapy-induced immunogenic cancer cell death. Journal of Experimental & Clinical Cancer Research 41:1.
Crossref
Crossref
Biaoru Li. (2022) Why do tumor-infiltrating lymphocytes have variable efficacy in the treatment of solid tumors?. Frontiers in Immunology 13.
Crossref
Crossref
Martina Chirra, Hannah S. Newton, Vaibhavkumar S. Gawali, Trisha M. Wise-Draper, Ameet A. Chimote & Laura Conforti. (2022) How the Potassium Channel Response of T Lymphocytes to the Tumor Microenvironment Shapes Antitumor Immunity. Cancers 14:15, pages 3564.
Crossref
Crossref
Alberto A. Chiappori, Ben Creelan, Tawee Tanvetyanon, Jhanelle E. Gray, Eric B. Haura, Ram Thapa, Margaret L. Barlow, Zhihua Chen, Dung Tsa Chen, Amer A. Beg, Theresa A. Boyle, Julio Castro, Liza Morgan, Erick Morris, Mehreteab Aregay, Felipe K. Hurtado, Luigi Manenti & Scott Antonia. (2022) Phase I Study of Taminadenant (PBF509/NIR178), an Adenosine 2A Receptor Antagonist, with or without Spartalizumab (PDR001), in Patients with Advanced Non–Small Cell Lung Cancer. Clinical Cancer Research 28:11, pages 2313-2320.
Crossref
Crossref
Gabrielle Sonigo, Alizée Bozonnat, Maëlle Dumont, Nicolas Thonnart, Caroline Ram-Wolff, Adèle de Masson, Martine Bagot, Armand Bensussan & Anne Marie-Cardine. (2022) Involvement of the CD39/CD73/adenosine pathway in T-cell proliferation and NK cell-mediated antibody-dependent cell cytotoxicity in Sézary syndrome. Blood 139:17, pages 2712-2716.
Crossref
Crossref
Julia S. L. Lim, Phyllis S. Y. Chong & Wee-Joo Chng. (2022) Metabolic Vulnerabilities in Multiple Myeloma. Cancers 14:8, pages 1905.
Crossref
Crossref
Lili Huang, Yeye Guo, Shujing Liu, Huaishan Wang, Jinjin Zhu, Lingling Ou & Xiaowei Xu. (2021) Targeting regulatory T cells for immunotherapy in melanoma. Molecular Biomedicine 2:1.
Crossref
Crossref
Elham Baghbani, Saeed Noorolyai, Dariush Shanehbandi, Ahad Mokhtarzadeh, Leili Aghebati-Maleki, Vahid Khaze Shahgoli, Oronzo Brunetti, Shima Rahmani, Mahdi Abdoli Shadbad, Amir Baghbanzadeh, Nicola Silvestris & Behzad Baradaran. (2021) Regulation of immune responses through CD39 and CD73 in cancer: Novel checkpoints. Life Sciences 282, pages 119826.
Crossref
Crossref
Magis Mandapathil, Miroslaw J. Szczepanski, Edwin K. Jackson, Stephan Lang & Theresa L. Whiteside. (2021) Breast Cancer Cell-Derived Adenosine Enhances Generation and Suppressor Function of Human Adaptive Regulatory T Cells. Journal of Personalized Medicine 11:8, pages 754.
Crossref
Crossref
Hannah S. Newton, Ameet A. Chimote, Michael J. Arnold, Trisha M. Wise-Draper & Laura Conforti. (2021) Targeted knockdown of the adenosine A2A receptor by lipid NPs rescues the chemotaxis of head and neck cancer memory T cells. Molecular Therapy - Methods & Clinical Development 21, pages 133-143.
Crossref
Crossref
Amir E. Wahba, Denise Fedele, Hoda Gebril, Enmar AlHarfoush, Kiran S. Toti, Kenneth A. Jacobson & Detlev Boison. (2021) Adenosine Kinase Expression Determines DNA Methylation in Cancer Cell Lines. ACS Pharmacology & Translational Science 4:2, pages 680-686.
Crossref
Crossref
Roberto Zefferino, Claudia Piccoli, Sante Di Gioia, Nazzareno Capitanio & Massimo Conese. (2021) How Cells Communicate with Each Other in the Tumor Microenvironment: Suggestions to Design Novel Therapeutic Strategies in Cancer Disease. International Journal of Molecular Sciences 22:5, pages 2550.
Crossref
Crossref
Soumya Panigrahi, Douglas A. Bazdar, Marwah Albakri, Brian Ferrari, Christopher J. Antonelli, Michael L. Freeman, George Dubyak, Chad Zender & Scott F. Sieg. (2020)
CD8
+
CD73
+
T cells in the tumor microenvironment of head and neck cancer patients are linked to diminished T cell infiltration and activation in tumor tissue
. European Journal of Immunology 50:12, pages 2055-2066.
Crossref
Crossref
Yuqing Cao, Xiaoyu Wang, Tianqiang Jin, Yu Tian, Chaoliu Dai, Crystal Widarma, Rui Song & Feng Xu. (2020) Immune checkpoint molecules in natural killer cells as potential targets for cancer immunotherapy. Signal Transduction and Targeted Therapy 5:1.
Crossref
Crossref
Young Mun Jeong, Haejin Cho, Tae-Min Kim, Yourha Kim, Sora Jeon, Andrey Bychkov & Chan Kwon Jung. (2020) CD73 Overexpression Promotes Progression and Recurrence of Papillary Thyroid Carcinoma. Cancers 12:10, pages 3042.
Crossref
Crossref
Michał Załuski, Jakub Schabikowski, Piotr Jaśko, Adrian Bryła, Agnieszka Olejarz-Maciej, Maria Kaleta, Monika Głuch-Lutwin, Andreas Brockmann, Sonja Hinz, Małgorzata Zygmunt, Kamil Kuder, Gniewomir Latacz, Christin Vielmuth, Christa E. Müller & Katarzyna Kieć-Kononowicz. (2020) 8-Benzylaminoxanthine scaffold variations for selective ligands acting on adenosine A2A receptors. Design, synthesis and biological evaluation. Bioorganic Chemistry 101, pages 104033.
Crossref
Crossref
Ana Mallo-Abreu, Rubén Prieto-Díaz, Willem Jespers, Jhonny Azuaje, Maria Majellaro, Carmen Velando, Xerardo García-Mera, Olga Caamaño, José Brea, María I. Loza, Hugo Gutiérrez-de-Terán & Eddy Sotelo. (2020)
Nitrogen-Walk Approach to Explore Bioisosteric Replacements in a Series of Potent A
2B
Adenosine Receptor Antagonists
. Journal of Medicinal Chemistry 63:14, pages 7721-7739.
Crossref
Crossref
Anaí del Rocío Campos-Contreras, Mauricio Díaz-Muñoz & Francisco G. Vázquez-Cuevas. (2020) Purinergic Signaling in the Hallmarks of Cancer. Cells 9:7, pages 1612.
Crossref
Crossref
Jingxing Yang & Chunfu Zhang. (2020) Regulation of cancer‐immunity cycle and tumor microenvironment by nanobiomaterials to enhance tumor immunotherapy. WIREs Nanomedicine and Nanobiotechnology 12:4.
Crossref
Crossref
Massimo Giuliani & Alessandro Poggi. (2020) Checkpoint Inhibitors and Engineered Cells: New Weapons for Natural Killer Cell Arsenal Against Hematological Malignancies. Cells 9:7, pages 1578.
Crossref
Crossref
Nils Ludwig, Juliana H. Azambuja, Aparna Rao, Delbert G. Gillespie, Edwin K. Jackson & Theresa L. Whiteside. (2020) Adenosine receptors regulate exosome production. Purinergic Signalling 16:2, pages 231-240.
Crossref
Crossref
Hitomi Sudo, Atsushi B. Tsuji, Aya Sugyo, Gene Kurosawa, Yoshikazu Kurosawa, David Alexander, Hiroyuki Tsuda, Tsuneo Saga & Tatsuya Higashi. (2020) Radiolabeled Human Monoclonal Antibody 067-213 has the Potential for Noninvasive Quantification of CD73 Expression. International Journal of Molecular Sciences 21:7, pages 2304.
Crossref
Crossref
N. Ludwig & M. T. Lotze. (2020) A treatise on endothelial biology and exosomes: homage to Theresa Maria Listowska WhitesideEndothelbiologie und Exosomen – eine Hommage auf Theresa Maria Listowska Whiteside. HNO 68:2, pages 71-79.
Crossref
Crossref
Nagore Del-Río-Ibisate, Rocío Granda-Díaz, Juan P. Rodrigo, Sofía T. Menéndez & Juana M. García-Pedrero. 2021. Transportome Malfunction in the Cancer Spectrum. Transportome Malfunction in the Cancer Spectrum
375
427
.
Linsen Shi, Min Feng, Shangce Du, Xu Wei, Hu Song, Xu Yixin, Jun Song & Guan Wenxian. (2019)
Adenosine Generated by Regulatory T Cells Induces CD8
+
T Cell Exhaustion in Gastric Cancer through A2aR Pathway
. BioMed Research International 2019, pages 1-10.
Crossref
Crossref
Georgi Atanasov, Karoline Dino, Katrin Schierle, Corinna Dietel, Gabriela Aust, Johann Pratschke, Daniel Seehofer, Moritz Schmelzle & Hans-Michael Hau. (2019) Immunologic cellular characteristics of the tumour microenvironment of hepatocellular carcinoma drive patient outcomes. World Journal of Surgical Oncology 17:1.
Crossref
Crossref
Constantin N. Baxevanis, Sotirios P. Fortis & Sonia A. Perez. (2019) The balance between breast cancer and the immune system: Challenges for prognosis and clinical benefit from immunotherapies. Seminars in Cancer Biology.
Crossref
Crossref
Gullanki Naga Venkata Charan Tej, Kaushik Neogi & Prasanta Kumar Nayak. (2019) Caffeine-enhanced anti-tumor activity of anti-PD1 monoclonal antibody. International Immunopharmacology 77, pages 106002.
Crossref
Crossref
Ana Mallo-Abreu, María Majellaro, Willem Jespers, Jhonny Azuaje, Olga Caamaño, Xerardo García-Mera, José M. Brea, María I. Loza, Hugo Gutiérrez-de-Terán & Eddy Sotelo. (2019)
Trifluorinated Pyrimidine-Based A
2B
Antagonists: Optimization and Evidence of Stereospecific Recognition
. Journal of Medicinal Chemistry 62:20, pages 9315-9330.
Crossref
Crossref
Adrián Tóth, Zsófia Antal, Dániel Bereczki & Beáta Sperlágh. (2019) Purinergic Signalling in Parkinson’s Disease: A Multi-target System to Combat Neurodegeneration. Neurochemical Research 44:10, pages 2413-2422.
Crossref
Crossref
Nabila Tounsi, Bahia Djerdjouri, Chafik Bouzid & Kamel Bentabak. (2019) Correlation of adenosine deaminase operating under nitro-oxidative stress with tumor and vascularization in patients with advanced gallbladder carcinoma. Journal of Applied Biomedicine 17:3, pages 175-183.
Crossref
Crossref
Peng He, Wenbo Zhou, Mingyao Liu & Yihua Chen. (2019) Recent Advances of Small Molecular Regulators Targeting G Protein- Coupled Receptors Family for Oncology Immunotherapy. Current Topics in Medicinal Chemistry 19:16, pages 1464-1483.
Crossref
Crossref
Gullanki Naga Venkata Charan Tej, Kaushik Neogi, Sumit Singh Verma, Subash Chandra Gupta & Prasanta Kumar Nayak. (2019) Caffeine-enhanced anti-tumor immune response through decreased expression of PD1 on infiltrated cytotoxic T lymphocytes. European Journal of Pharmacology 859, pages 172538.
Crossref
Crossref
Petros Grivas, Alexandra Drakaki, Terence W. Friedlander & Guru Sonpavde. (2019) Conceptual Framework for Therapeutic Development Beyond Anti–PD-1/PD-L1 in Urothelial Cancer. American Society of Clinical Oncology Educational Book:39, pages 284-300.
Crossref
Crossref
J. H. Azambuja, N. E. Gelsleichter, L. R. Beckenkamp, I. C. Iser, M. C. Fernandes, F. Figueiró, A. M. O. Battastini, J. N. Scholl, F. H. de Oliveira, R. M. Spanevello, Jean Sévigny, M. R. Wink, M. A. Stefani, H. F. Teixeira & Elizandra Braganhol. (2018) CD73 Downregulation Decreases In Vitro and In Vivo Glioblastoma Growth. Molecular Neurobiology 56:5, pages 3260-3279.
Crossref
Crossref
Alberto L. Horenstein, Cristiano Bracci, Fabio Morandi & Fabio Malavasi. (2019) CD38 in Adenosinergic Pathways and Metabolic Re-programming in Human Multiple Myeloma Cells: In-tandem Insights From Basic Science to Therapy. Frontiers in Immunology 10.
Crossref
Crossref
Sebastián Alarcón, Ignacio Niechi, Fernando Toledo, Luis Sobrevia & Claudia Quezada. (2019) Glioma progression in diabesity. Molecular Aspects of Medicine 66, pages 62-70.
Crossref
Crossref
Maarit K Koivisto, Minna Tervahartiala, István Kenessey, Sirpa Jalkanen, Peter J Boström & Marko Salmi. (2019) Cell-type-specific CD73 expression is an independent prognostic factor in bladder cancer. Carcinogenesis 40:1, pages 84-92.
Crossref
Crossref
Hailong Ma, Wenyi Yang, Liming Zhang, Shuli Liu, Mei Zhao, Ge Zhou, Lizhen Wang, Shufang Jin, Zhiyuan Zhang & Jingzhou Hu. (2018) Interferon-alpha promotes immunosuppression through IFNAR1/STAT1 signalling in head and neck squamous cell carcinoma. British Journal of Cancer 120:3, pages 317-330.
Crossref
Crossref
Guoping Liu, Wei Zhang, Jie Guo, Fanqiang Kong, Shumin Zhou, Song Chen, Zhiyun Wang & Dawei Zang. (2018) Adenosine binds predominantly to adenosine receptor A1 subtype in astrocytes and mediates an immunosuppressive effect. Brain Research 1700, pages 47-55.
Crossref
Crossref
Wei Zhang, Shumin Zhou, Guoping Liu, Fanqiang Kong, Song Chen & Hua Yan. (2018) Multiple steps determine CD73 shedding from RPE: lipid raft localization, ARA1 interaction, and MMP-9 up-regulation. Purinergic Signalling 14:4, pages 443-457.
Crossref
Crossref
Andrea M. Chambers, Kyle B. Lupo & Sandro Matosevic. (2018) Tumor Microenvironment-Induced Immunometabolic Reprogramming of Natural Killer Cells. Frontiers in Immunology 9.
Crossref
Crossref
Linsen Shi, Lin Yang, Zhaoyin Wu, Wei Xu, Jun Song & Wenxian Guan. (2018) Adenosine signaling: Next checkpoint for gastric cancer immunotherapy?. International Immunopharmacology 63, pages 58-65.
Crossref
Crossref
Ming Liu & Fukun Guo. (2018) Recent updates on cancer immunotherapy. Precision Clinical Medicine 1:2, pages 65-74.
Crossref
Crossref
Jiao Wang & Sandro Matosevic. (2018) Adenosinergic signaling as a target for natural killer cell immunotherapy. Journal of Molecular Medicine 96:9, pages 903-913.
Crossref
Crossref
Ritu Shrestha, Prashanth Prithviraj, Matthew Anaka, Kim R. Bridle, Darrell H. G. Crawford, Bijay Dhungel, Jason C. Steel & Aparna Jayachandran. (2018) Monitoring Immune Checkpoint Regulators as Predictive Biomarkers in Hepatocellular Carcinoma. Frontiers in Oncology 8.
Crossref
Crossref
Yiqing Cai, Lili Feng & Xin Wang. (2018) Targeting the tumor promoting effects of adenosine in chronic lymphocytic leukemia. Critical Reviews in Oncology/Hematology 126, pages 24-31.
Crossref
Crossref
Ágatha Oliveira-Giacomelli, Yahaira Naaldijk, Laura Sardá-Arroyo, Maria C. B. Gonçalves, Juliana Corrêa-Velloso, Micheli M. Pillat, Héllio D. N. de Souza & Henning Ulrich. (2018) Purinergic Receptors in Neurological Diseases With Motor Symptoms: Targets for Therapy. Frontiers in Pharmacology 9.
Crossref
Crossref
Mansi Saxena & Nina Bhardwaj. (2018) Re-Emergence of Dendritic Cell Vaccines for Cancer Treatment. Trends in Cancer 4:2, pages 119-137.
Crossref
Crossref
Theresa L. Whiteside. (2018) Head and Neck Carcinoma Immunotherapy: Facts and Hopes. Clinical Cancer Research 24:1, pages 6-13.
Crossref
Crossref
Oliver Kepp, Friedemann Loos, Peng Liu & Guido Kroemer. (2017) Extracellular nucleosides and nucleotides as immunomodulators. Immunological Reviews 280:1, pages 83-92.
Crossref
Crossref
Chang-Sook Hong, Priyanka Sharma, Saigopalakrishna S. Yerneni, Patricia Simms, Edwin K. Jackson, Theresa L. Whiteside & Michael Boyiadzis. (2017) Circulating exosomes carrying an immunosuppressive cargo interfere with cellular immunotherapy in acute myeloid leukemia. Scientific Reports 7:1.
Crossref
Crossref